Lin BioScience, Inc.
6696
Rang in Aktien
#3772
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Aktienkurs
$5.34
Marktkapitalisierung
$4.43B
Veränderung (1 Tag)
3.07%
Veränderung (1 Jahr)
-39.48%
Land
TW
Handel Lin BioScience, Inc. (6696)
Kategorie
Healthcare
Kursverlauf für Lin BioScience, Inc. (6696)
Höchster Schlusskurs: $5.43 am 2026-10-01
Niedrigster Schlusskurs: $1.30 am 2018-10-01
Niedrigster Schlusskurs: $1.30 am 2018-10-01
Kursverlauf der Aktie von Lin BioScience, Inc. von 2018 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -4.02% |
| 2025 | 202.95% |
| 2024 | 13.59% |
| 2023 | -31.65% |
| 2022 | -22.82% |
| 2021 | 101.12% |
| 2020 | 278.57% |
| 2019 | -21.27% |
| 2018 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $137.75 | -3.72% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
